Dr Reddy’s subsidiary told to halt phase III trial of lung cancer drug eftilagimod alfa

Enrolment in the study is being halted in response to the Independent Data Monitoring Committee’s recommendation. Shares of Dr Reddy’s Laboratories Ltd ended at ₹1,288.40, down by ₹30.35, or 2.30%, on the BSE today, March 13.








